Financiere des Professionnels Fonds d investissement inc. Buys New Shares in Medpace Holdings, Inc. $MEDP

Key Points

• Financiere des Professionnels Fonds d'investissement inc. has invested $230,000 in Medpace Holdings by acquiring 732 shares in the second quarter.
• Several large investors have increased their stakes in Medpace, with Northern Trust Corp. raising their investment by 36% during the first quarter.
• Analysts have mixed views on Medpace's stock, with Barclays raising the target price to $450 while other firms have downgraded their ratings.

Financiere des Professionnels Fonds d investissement inc. purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 732 shares of the company's stock, valued at approximately $230,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. GAMMA Investing LLC grew its holdings in shares of Medpace by 37.1% during the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company's stock worth $94,000 after acquiring an additional 83 shares during the period. Inspire Investing LLC bought a new stake in shares of Medpace during the first quarter valued at approximately $2,059,000. Voya Investment Management LLC grew its stake in Medpace by 7.6% in the first quarter. Voya Investment Management LLC now owns 21,976 shares of the company's stock worth $6,696,000 after purchasing an additional 1,560 shares during the period. Zeno Equity Partners LLP raised its holdings in Medpace by 2.6% in the first quarter. Zeno Equity Partners LLP now owns 62,304 shares of the company's stock worth $18,983,000 after purchasing an additional 1,564 shares in the last quarter. Finally, United Services Automobile Association bought a new position in Medpace in the first quarter worth $500,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on MEDP shares. Mizuho boosted their target price on shares of Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Jefferies Financial Group raised their target price on shares of Medpace from $400.00 to $450.00 and gave the company a "hold" rating in a research note on Tuesday, September 9th. TD Cowen reiterated a "sell" rating and set a $366.00 price objective (up previously from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Finally, UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and upped their target price for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, Medpace has an average rating of "Reduce" and an average target price of $422.27.

Medpace Stock Performance

Shares of NASDAQ MEDP traded down $0.52 during midday trading on Monday, hitting $498.08. 155,854 shares of the stock traded hands, compared to its average volume of 316,492. The firm has a market capitalization of $13.99 billion, a P/E ratio of 37.03, a PEG ratio of 3.14 and a beta of 1.44. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $506.55. The firm has a 50-day moving average of $450.44 and a two-hundred day moving average of $356.61.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, VP Susan E. Burwig sold 10,000 shares of the firm's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total value of $4,800,000.00. Following the transaction, the vice president directly owned 57,500 shares of the company's stock, valued at approximately $27,600,000. This trade represents a 14.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at $4,654,350. This represents a 22.48% decrease in their position. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock valued at $74,111,427 in the last quarter. Insiders own 20.30% of the company's stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.